Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Antineoplastics

Antineoplastics Reactions 1704, p38 - 2 Jun 2018 Various toxicities and drug resistance leading to treatment failure: case report A 32-year-old woman developed hair loss, vomiting and neutropenia following treatment with etoposide, methotrexate, dactinomycin [Act-D], cyclophosphamide and vincristine for gestational trophoblastic neoplasia. Additionally, she developed resistance to methotrexate leading to treatment failure for gestational trophoblastic neoplasia [routes, durations of treatments to reactions onsets and outcomes not stated]. The woman (Gravida 2 para 0), who had metastatic gestational trophoblastic neoplasia, received single-agent chemotherapy with methotrexate. However, she developed resistance to methotrexate, leading to treatment failure. Hence multi-agent treatment (EMA-CO regimen) with etoposide, methotrexate, dactinomycin, cyclophosphamide and vincristine was started. Subsequently, she developed hair loss, vomiting and neutropenia. She received the EMA-CO regimen for a total duration of 5 months. Author comment: "[T]reatment with EMA-CO was generally well tolerated and toxicity was mild. In our case, there was no life-threatening toxicity, but hair loss, vomiting and neutropenia occurred. After suction evacuation, initially single agent chemotherapy using Methotrexate was done. However, this treatment failed. The patient with metastatic low risk GTN that developed resistance to single-agent chemotherapy achieved remission with combination chemotherapy." Han JS, et al. Coexisting complete hydatidiform mole and live foetus: http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Antineoplastics

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Antineoplastics

Abstract

Reactions 1704, p38 - 2 Jun 2018 Various toxicities and drug resistance leading to treatment failure: case report A 32-year-old woman developed hair loss, vomiting and neutropenia following treatment with etoposide, methotrexate, dactinomycin [Act-D], cyclophosphamide and vincristine for gestational trophoblastic neoplasia. Additionally, she developed resistance to methotrexate leading to treatment failure for gestational trophoblastic neoplasia [routes, durations of treatments to reactions...
Loading next page...
 
/lp/springer-journals/antineoplastics-MiaQCt8se2
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46681-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p38 - 2 Jun 2018 Various toxicities and drug resistance leading to treatment failure: case report A 32-year-old woman developed hair loss, vomiting and neutropenia following treatment with etoposide, methotrexate, dactinomycin [Act-D], cyclophosphamide and vincristine for gestational trophoblastic neoplasia. Additionally, she developed resistance to methotrexate leading to treatment failure for gestational trophoblastic neoplasia [routes, durations of treatments to reactions onsets and outcomes not stated]. The woman (Gravida 2 para 0), who had metastatic gestational trophoblastic neoplasia, received single-agent chemotherapy with methotrexate. However, she developed resistance to methotrexate, leading to treatment failure. Hence multi-agent treatment (EMA-CO regimen) with etoposide, methotrexate, dactinomycin, cyclophosphamide and vincristine was started. Subsequently, she developed hair loss, vomiting and neutropenia. She received the EMA-CO regimen for a total duration of 5 months. Author comment: "[T]reatment with EMA-CO was generally well tolerated and toxicity was mild. In our case, there was no life-threatening toxicity, but hair loss, vomiting and neutropenia occurred. After suction evacuation, initially single agent chemotherapy using Methotrexate was done. However, this treatment failed. The patient with metastatic low risk GTN that developed resistance to single-agent chemotherapy achieved remission with combination chemotherapy." Han JS, et al. Coexisting complete hydatidiform mole and live foetus:

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References